At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 218 enrolled
Drug / intervention
Lacosamide +2 moredrug
Likely dose
Lacosamide 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
In Brief
A Phase 2 clinical trial evaluating Lacosamide and Placebo for Migraine. Completed, enrolled 218 participants across 24 sites.
Detailed Summary
The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedFeb 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedFeb 27, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.3 years ago
Interventions
Lacosamidedrug
Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
Placeboother
Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
Lacosamidedrug
Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.